(−)-Gossypol Inhibits Growth and Promotes Apoptosis of Human Head and Neck Squamous Cell Carcinoma In Vivo

Todd, 1997, The molecular biology of oral carcinogenesis: toward a tumor progression model, J Oral Maxillofac Surg, 55, 613, 10.1016/S0278-2391(97)90495-X 1991, Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer, N Engl J Med, 324, 1685, 10.1056/NEJM199106133242402 Eastman, 1990, Activation of programmed cell death by anticancer agents: cisplatin as a model system, Cancer Cells, 2, 275 Hickman, 1992, Apoptosis induced by anticancer drugs, Cancer Metastasis Rev, 11, 121, 10.1007/BF00048059 Trask, 2002, Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation, Laryngoscope, 112, 638, 10.1097/00005537-200204000-00009 Oliver, 2004, In vitro effects of the BH3 mimetic, (−)-gossypol, on head and neck squamous cell carcinoma cells, Clin Cancer Res, 10, 7757, 10.1158/1078-0432.CCR-04-0551 Bauer, 2005, Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL, Mol Cancer Ther, 4, 1096, 10.1158/1535-7163.MCT-05-0081 Fesik, 2005, Promoting apoptosis as a strategy for cancer drug discovery, Nat Rev Cancer, 5, 876, 10.1038/nrc1736 Wang, 2000, Cytotoxic effect of gossypol on colon carcinoma cells, Life Sci, 67, 2663, 10.1016/S0024-3205(00)00857-2 Zhang, 2003, Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells, Biochem Pharmacol, 66, 93, 10.1016/S0006-2952(03)00248-X Van Poznak, 2001, Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial, Breast Cancer Res Treat, 66, 239, 10.1023/A:1010686204736 Blackstaffe, 1997, Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines, Melanoma Res, 7, 364, 10.1097/00008390-199710000-00002 Kitada, 2003, Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins, J Med Chem, 46, 4259, 10.1021/jm030190z Carey, 1994, Head and neck tumor cell lines, 79 Mitra, 2003, RaplA and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form, Oncogene, 22, 6243, 10.1038/sj.onc.1206534 D'Silva, 2003, Rapi, a small GTP-binding protein, is upregulated during arrest of proliferation in human keratinocytes, J Cell Physiol, 196, 532, 10.1002/jcp.10331 Mohammad, 2005, Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(−)-gossypol] against diffuse large cell lymphoma, Mol Cancer Ther, 4, 13, 10.1186/1476-4598-4-13 Hopkins-Donaldson, 2003, Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl2 and Bcl-xL antisense treatment, Int J Cancer, 106, 160, 10.1002/ijc.11209 Liu, 1997, Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in BCI-xL and bak expression, Clin Cancer Res, 3, 2039 Liu, 1998, BCI-xL is expressed in ovarian carcinoma and modulates chemotherapyinduced apoptosis, Gynecol Oncol, 70, 398, 10.1006/gyno.1998.5125 Reed, 1996, Mechanisms of Bcl-2 family protein function and dysfunction in health and disease, Behring-Inst-Mitt, 72 Huang, 2000, Bcl-2 family proteins as targets for anticancer drug design, Oncogene, 19, 6627, 10.1038/sj.onc.1204087 Klasa, 2002, Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment, Antisense Nucleic Acid Drug Dev, 12, 193, 10.1089/108729002760220798 Kutzki, 2002, Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry, J Am Chem Soc, 124, 11838, 10.1021/ja026861k Tzung, 2001, Antimycin A mimics a celldeath-inducing Bcl-2 homology domain 3, Nat Cell Biol, 3, 183, 10.1038/35055095 Becattini, 2004, Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting BclX(L), Chem Biol, 11, 389, 10.1016/j.chembiol.2004.02.020 Wang, 2000, Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells, Proc Natl Acad Sci USA, 97, 7124, 10.1073/pnas.97.13.7124 Oltersdorf, 2005, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, 435, 677, 10.1038/nature03579 Prime, 2004, Metastatic dissemination of human malignant oral keratinocyte cell lines following orthotopic transplantation reflects response to TGF-beta 1, J Pathol, 203, 927, 10.1002/path.1603 Osaki, 2004, Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45, J Cancer Res Clin Oncol, 130, 8, 10.1007/s00432-003-0505-z Watanabe, 2005, A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo, Int J Cancer, 114, 32, 10.1002/ijc.20688 Zhong, 2004, Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells, Int J Oncol, 25, 445 Hayward, 2003, Antisense Bcl-xL down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity, Clin Cancer Res, 9, 2856 Jarvis, 1994, Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C, Cancer Res, 54, 1707 Coyle, 1994, In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines, J Neuro-Oncol, 19, 25, 10.1007/BF01051046 Ligueros, 1997, Gossypol inhibition of mitosis, cyclin DI and Rb protein in human mammary cancer cells and cyclin-DI transfected human fibrosarcoma cells, Br J Cancer, 76, 21, 10.1038/bjc.1997.330 Hou, 2004, Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis, Arch Biochem Biophys, 428, 179, 10.1016/j.abb.2004.06.007